Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering DrugsHye Won Lee, Su‐Yen Goh, Marcus Thuresson et al.|Journal of the American College of Cardiology|2018Cited by 465
SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in EuropeLisa Pennells, Panagiotis Vardas, Stephen Kaptoge et al.|European Heart Journal|2023Cited by 299
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyShun Kohsaka, Dianna J. Magliano, Matthias Saathoff et al.|The Lancet Diabetes & Endocrinology|2020Cited by 93